This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Eliot Siegel, MD; Stanislav Spiridonov, MD; Nathan Gee, MD; and Anthony Chang, PhD, are among a niche gathering of early adopters, entrepreneurial physicians, medical physicists, and investors with a sweet spot for nuclearmedicine, diagnostic radiology, and radiation oncology.
CHICAGO -- GE HealthCare (GEHC) brought new CT and MRI scanners and a range of AI software applications to McCormick Place for RSNA 2023. GE HealthCare's new Revolution Ascend CT scanner. GE HealthCare's Signa Champion 1.5-tesla tesla scanner.
GE HealthCare expects to leverage MIM Software’s imaging analytics and digital workflow capabilities across various care areas to accelerate innovation and differentiate its solutions for the benefit of patients and healthcare systems around the world.
-based radioisotope production is already helping to meet a vital need for patients, and the Company is strongly positioned for sustained rapid growth as we pioneer new horizons to help meet patients’ healthcare needs with game-changing radiopharmaceuticals.” I greatly look forward to continuing to work with Frank in his new role as CEO.
Marco Campione brings more than 25 years of experience from GE HealthCare, where he most recently served as Executive Director and Global Head of Contrast Media, General Manager Pharmaceutical Diagnostics North America and President GE HealthCare Inc., according to a written statement announcing the appointment. “I
GE HealthCare’s Cerianna , available in the U.S., We are delighted to see the inclusion of Cerianna PET in the NCCN breast oncology guidelines, for potential use when oncologists are evaluating metastatic breast cancer patients,” Dr. Mark Hibberd, Chief Medical Officer at GE HealthCare’sPharmaceutical Diagnostics segment, said.
For pharmaceutical companies and researchers, using this tracer to better understand the mechanism of action - i.e. the effect of immunotherapies on a patient’s immune response to their cancer - could, potentially, enable them to better select patients to participate in clinical trials and bring new immunotherapies to market.
Prior to joining NorthStar, Mr. Vinyard spent 16 years in roles of increasing responsibility at Mallinckrodt/Curium, where he was most recently Global Director of Business Development for Curium’s Active Pharmaceutical Ingredient business and held responsibility for a considerable portion of its U.S. Francis in Joliet, Ill.,
The FibroScint program, a collaboration with Capella Imaging, to develop a Tc-99m agent to image fibrin, and collaboration with GE Healthcare to manufacture I-123 capsules are on track for further advancement this year. Merrick concluded, “This is a very exciting and dynamic time for NorthStar and all those involved in nuclearmedicine.
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content